1461093500-3d702439-2e32-4218-bc50-6caac7043774

1. A powder for oral suspension comprising greater than 4.2% by weight of cefdinir.
2. A powder for oral suspension comprising about 6% to about 10% by weight of cefdinir.
3. A powder for oral suspension comprising at least 8.4% by weight cefdinir.
4. A powder for oral suspension comprising
(a) at least 8.4% by weight cefdinir;
(b) a diluent; and
(c) a buffering agent.
5. A powder for oral suspension of claim 4 wherein the diluent is selected from the group consisting of sucrose, sorbitol, xylitol, dextrose, fructose, malitol, sugar potassium, aspartame, saccharin, saccharin sodium, and mixtures thereof.
6. A powder for oral suspension of claim 5 wherein the diluent is sucrose.
7. A powder for oral suspension of claim 4 wherein the buffering agent is selected from the group consisting of citric acid, sodium citrate, sodium phosphate, potassium citrate, and mixtures thereof.
8. A powder for oral suspension of claim 7 wherein the buffering agent is a mixture of citric acid and sodium citrate.
9. A powder for oral suspension comprising:
(a) about 8.4% by weight cefdinir;
(b) about 89.2% by weight diluent;
(c) about 0.26% by weight buffering agent;
(d) about 0.16% by weight preservative;
(e) about 0.33% by weight viscosity enhancer;
(f) about 1.31% by weight flavoring agent;
(g) about 0.07% glidant; and
(h) about 0.35% lubricant.
10. A powder for oral suspension of claim 9 wherein the diluent is selected from the group consisting of sucrose, sorbitol, xylitol, dextrose, fructose, malitol, sugar potassium, aspartame, saccharin, saccharin sodium, and mixtures thereof.
11. A powder for oral suspension of claim 10 wherein the diluent is sucrose.
12. A powder for oral suspension of claim 9 wherein the buffering agent is selected from the group consisting of citric acid, sodium citrate, sodium phosphate, potassium citrate, and mixtures thereof.
13. A powder for oral suspension of claim 12 wherein the buffering agent is a mixture of citric acid and sodium citrate.
14. A powder for oral suspension of claim 9 wherein the preservative is selected from the group consisting of sodium benzoate, benzoic acid, ethylenediaminetetraacetic acid, sorbic acid, benzethonium chloride, benzalkonium chloride, bronopol, butyl paraben, methyl paraben, ethylparaben, propyl paraben, thiomerosol, sodium propionate, chlorhexidine, chlorobutanol, chlorocresol, cresol, imidurea, phenol, phenylmercuric salts, potassium sorbate, propylene glycol, and mixtures thereof.
15. A powder for oral suspension of claim 14 wherein the preservative is sodium benzoate.
16. A powder for oral suspension of claim 9 wherein the viscosity enhancing agent is selected from the group consisting of xantham gum, guar gum, acacia, povidone, alginic acid, sodium alginate, propylene glycol alginate, carbomer, carboxymethylcellulose calcium, carboxymethylcellulose sodium, ethylcellulose, gelatin, ethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polydextrose, carrageenan, methylcellulose, sucrose, sorbitol, xylitol, dextrose, fructose, malitol, sugar, sodium alginate, tragacanth, hydroxypropyl methylcellulose, bentonite, a polyvinyl alcohol, cetearyl alcohol, colloidal silicon dioxide, and mixtures thereof.
17. A powder for oral suspension of claim 16 wherein the viscosity enhancing agent is a mixture of xantham gum and guar gum.
18. A powder for oral suspension of claim 9 wherein the glidant is selected from the group consisting of colloidal silicon dioxide, talc, fumed silica, magnesium stearate, calcium stearate, magnesium trisilicate, powdered cellulose, starch, tribasic calcium phosphate, and mixtures thereof.
19. A powder for oral suspension of claim 18 wherein the glidant is colloidal silicon dioxide.
20. A powder for oral suspension of claim 9 wherein the lubricant is selected from the group consisting of magnesium stearate, calcium stearate, zinc stearate, magnesium oxide, stearic acid, sodium stearyl fumarate, sodium lauryl stearate, hydrogenated vegetable oil, corn starch, colloidal silicon dioxide, talc, and mixtures thereof.
21. A powder for oral suspension of claim 20 wherein the lubricant is magnesium stearate.
22. A powder for oral suspension comprising:
(a) about 8.36% by weight cefdinir;
(b) about 89.16% by weight sucrose;
(c) about 0.16% by weight citric acid;
(d) about 0.10% by weight sodium citrate;
(e) about 0.16% by weight sodium benzoate;
(f) about 0.16% by weight xantham gum;
(g) about 0.16% by weight guar gum;
(h) about 1.31% by weight flavoring agent;
(i) about 0.06% colloidal silicon dioxide; and
(j) about 0.35% magnesium stearate.
23. A method of treating acute bacterial otitis media, pharyngitis and tonsillitis with a oral suspension of cefdinir wherein said suspension is made by reconstituting a powder comprising greater than 4.2% by weight of cefdinir.
24. A method of treating acute bacterial otitis media, pharyngitis and tonsillitis with a oral suspension of cefdinir wherein said suspension is made by reconstituting a powder comprising at least 8.4% cefdinir.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound of the following formula:
M-(BM)n

wherein
M is a radionuclide that is a positron emitter;
n is an integer from 1to 10; and
BM is an SR-A antagonist of formula:
wherein
R1 is independently selected from: H, R1-benzamido, R1-benzylether, R1-benzylamino, amino, fluoralkyl, halo, cyano, nitro, aryloxyl, haloaryl, aryl, alkoxy, an 1,2-benzo; or R1 represents a fused ring forming naphthalene moiety with the six membered aryl ring it substitutes;
R2 is a direct bond to M; and
m is an integer from 1 to 4;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 wherein said radionuclide is 18F or 11C.
3. The compound of claim 2 wherein said radionuclide is 18F.
4. A compound of the following formula:
M-(BM)n

wherein,
M is radionuclide that is a positron emitter;
n is an integer from 1 to 10; and
BM is an SR-A antagonist of formula:
wherein
R1 is independently selected from: H, R1-benzamido, R1-benzylether, R1-benzylamino, amino, fluoralkyl, halo, cyano, nitro, aryloxyl, haloaryl, aryl, alkoxy, an 1,2-benzo; or R represents a fused ring forming naphthalene moiety with the six membered aryl ring it substitutes;
R2 is a direct bond to M;
m is an integer from 1 to 4;
M\u2032 is a metal ion selected from Fe(III, Os(III), Co(III), Ni(II), Cu(II), Mn(IJ), o Al(III);
M\u2033 is a metal-containing moiety selected from: V\u2550O, MO\u2550O, Re\u2550O, or Tc\u2550O; d
L is a coligand selected from: trialkylphosphine, triarylphosphine, triarylyalkylphosphine, pyridine or pyridine analog with appropriate substituent on the pyridine ring;
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 4 wherein:
M\u2032 is a metal ion selected from Fe(III, Os(III), Co(III), Ni(II), or Cu(II); and M\u2033 is a metal-containing moiety selected from: V\u2550O, Mo\u2550O, or Re\u2550O.
6. The compound of claim 5 wherein said radionuclide is 18F or 11C.
7. The compound of claim 6 wherein said radionuclide is 18F.
8. A method to diagnose a cardiovascular disease in a patient comprising administering to the patient in need of such diagnosis an effective amount of a compound of claim 1 and detecting the presence of the compound.
9. The method of claim 8 wherein the cardiovascular disease is selected from: atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
10. A method to diagnose a cardiovascular disease in a patient comprising administering to the patient in need of such diagnosis an effective amount of a compound of claim 3 and detecting the presence of the compound.
11. The method of claim 10 wherein the cardiovascular disease is selected from: atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
12. A method to monitor a cardiovascular disease in a patient comprising administering to the patient in need of such monitoring an effective amount of a compound of claim 1 and detecting the presence of the compound.
13. The method of claim 12 wherein the cardiovascular disease is selected from: atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
14. A method to monitor a cardiovascular disease in a patient comprising administering to the patient in need of such monitoring an effective amount of a compound of claim 3 and detecting the presence of the compound.
15. The method of claim 14 wherein the cardiovascular disease is selected from: atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
16. A method to monitor the progression of an atherosclerotic lesion in a patient comprising administering to the patient in need of such monitoring an effective amount of a compound of claim 1 and detecting the presence of the compound.
17. A method to detect vulnerable plaque comprising administering to the patient in need of such detection a compound of claim 1 and detecting the presence of the compound.
18. A method to monitor the progression of an atherosclerotic lesion in a patient comprising administering to the patient in need of such monitoring an effective amount of a compound of claim 3 and detecting the presence of the compound.
19. A method to detect vulnerable plaque comprising administering to the patient in need of such detection a compound of claim 3 and detecting the presence of the compound.
20. The method of claim 8 wherein the detection comprises positron emission tomography.
21. The method of claim 10 wherein the detection comprises positron emission tomography.
22. A method to diagnose a cardiovascular disease in a patient comprising administering the patient in need of such diagnosis an effective amount of a compound of claim 4 and detecting the presence of the compound.
23. The method of claim 22 wherein the cardiovascular disease is selected from: atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
24. A method to diagnose a cardiovascular disease in a patient comprising administering the patient in need of such diagnosis an effective amount of a compound of claim 7 and detecting the presence of the compound.
25. The method of claim 24 wherein the cardiovascular disease is selected from: atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
26. A method to monitor a cardiovascular disease in a patient comprising administering to the patient in need of such monitoring an effective amount of a compound of claim 4 and detecting the presence of the compound.
27. The method of claim 26 wherein the cardiovascular disease is selected from: atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
28. A method to monitor a cardiovascular disease in a patient comprising administering to the patient in need of such monitoring an effective amount of a compound of claim 7 and detecting the presence of the compound.
29. The method of claim 28 wherein the cardiovascular disease is selected from: atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
30. A method to monitor the progression of an atherosclerotic lesion in a patient comprising administering to the patient in need of such monitoring an effective amount of a compound of claim 4 and detecting the presence of the compound.
31. A method to monitor the progression of an atherosclerotic lesion in a patient comprising administering to the patient in need of such monitoring an effective amount of a compound of claim 7 and detecting the presence of the compound.
32. A method to detect vulnerable plaque comprising administering to the patient in need of such detection a compound of claim 4 and detecting the presence of the compound.
33. A method to detect vulnerable, plaque comprising administering to the patient in need of such detection a compound of claim 7 and detecting the presence of the compound.
34. The method of claim 22 wherein the detection comprises positron emission tomography.
35. The method of claim 24 wherein the detection comprises positron emission tomography.
36. A pharmaceutical composition comprising a predetermined quantity of a compound of claim 1, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or diluent.
37. The pharmaceutical composition of claim 36 further comprising an effective amount of a stabilizer.
38. The pharmaceutical composition of claim 37 wherein the stabilizer is selected from the group: ascorbic acid, benzyl alcohol, gentisic acid or a metal salt thereof, p-aminobenzoic acid or a salt thereof, cysteamine, 5-amino-2-hydroxybenzoic acid or a metal salt thereof; nicotinic acid or a metal salt thereof, nicotinamide, a polyhydroxylated aromatic compound, an aromatic amine, and a hydroxylated aromatic amine.
39. A pharmaceutical composition comprising a predetermined quantity of a compound of claim 3, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or diluent.
40. The pharmaceutical composition of claim 39 further comprising an effective amount of a stabilizer.
41. The pharmaceutical composition of claim 40 wherein the stabilizer is selected from the group: ascorbic acid, benzyl alcohol, gentisic acid or a metal salt thereof, p-aminobenzoic acid or a salt thereof, cysteamine, 5-amino-2-hydroxybenzoic acid or a metal salt thereof, nicotinic acid or a metal salt thereof, nicotinamide, a polyhydroxylated aromatic compound, an aromatic amine, and a hydroxylated aromatic amine.
42. A pharmaceutical composition comprising a predetermined quantity of a compound of claim 4 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or diluent.
43. The pharmaceutical composition of claim 42 further comprising an effective amount of a stabilizer.
44. The pharmaceutical composition of claim 43 wherein the stabilizer is selected from the group: ascorbic acid, benzyl alcohol, gentisic acid or a metal salt thereof, p-aminobenzoic acid or a salt thereof, cysteamine, 5-amino-2-hydroxybenzoic acid or a metal salt thereof, nicotinic acid or a metal salt thereof, nicotinamide, a polyhydroxylated aromatic compound, an aromatic amine, and a hydroxylated aromatic amine.
45. A pharmaceutical composition comprising a predetermined quantity of a compound of claim 7, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or diluent.
46. The pharmaceutical composition of claim 45 further comprising an effective amount of a stabilizer.
47. The pharmaceutical composition of claim 46 wherein the stabilizer is selected from the group: ascorbic acid, benzyl alcohol, gentisic acid or a metal salt thereof, p-aminobenzoic acid or a salt thereof, cysteamine, 5-amino-2-hydroxybenzoic acid or a metal salt thereof, nicotinic acid or a metal salt thereof, nicotinamide, a polyhydroxylated aromatic compound, an aromatic amine, and a hydroxylated aromatic amine.
48. A kit comprising a sealed vial comprising a predetermined quantity of a compound of claim 1 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or diluent.
49. The kit of claim 48 further comprising at least one of a reducing agent, a bulking agent, or a weak transfer ligand.
50. A kit comprising a sealed vial comprising a predetermined quantity of a compound of claim 3 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
51. The kit of claim 50 further comprising at least one of a reducing agent, a bulking agent, or a weak transfer ligand.
52. A kit comprising a sealed vial comprising a predetermined quantity of a compound of claim 4 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or diluent.
53. The kit of claim 52 further comprising at least one of a reducing agent, a bulking agent, or a weak transfer ligand.
54. A kit comprising a sealed vial comprising a predetermined quantity of a compound of claim 7 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or diluent.
55. The kit of claim 54 further comprising at least one of a reducing agent, a bulking agent, or a weak transfer ligand.
56. A kit comprising (a) a first vial comprising a predetermined quantity of a compound of claim 1, or a pharmaceutically acceptable salt thereof; and (b) a second vial comprising a pharmaceutically acceptable carrier or diluent.
57. The kit of claim 56 further comprising at least one of a reducing agent, a bulking agent, or a weak transfer ligand.
58. A kit comprising (a) a first vial comprising a predetermined quantity of a compound of claim 3, or a pharmaceutically acceptable salt thereof; and (b) a second vial comprising a pharmaceutically acceptable carrier or diluent.
59. The kit of claim 58 further comprising at least one of a reducing agent, a bulking agent, or a weak transfer ligand.
60. A kit comprising (a) a first vial comprising a predetermined quantity of a compound of claim 4, or a pharmaceutically acceptable salt thereof; and (b) a second vial comprising a pharmaceutically acceptable carrier or diluent.
61. The kit of claim 60 further comprising at least one of a reducing agent, a bulking agent, or a weak transfer ligand.
62. A kit comprising (a) a first vial comprising a predetermined quantity of a compound of claim 7, or a pharmaceutically acceptable salt thereof; and (b) a second vial comprising a pharmaceutically acceptable carrier or diluent.
63. The kit of claim 62 further comprising at least one of a reducing agent, a bulking agent, or a weak transfer ligand.

1461093489-faafa872-30a5-4e3c-9ff2-3d30eec1ed2d

1. A method of forming a trench capacitor in a substrate comprising the steps of:
etching a trench having substantially vertical sidewalls;
depositing a thermally stable filler material in the trench;
annealing the filler material in an oxidizing ambient;
recessing the filler material down to a capacitor top level;
forming insulating spacers on the trench sidewalls above the capacitor top level;
stripping the filler material;
doping the trench sidewalls below the spacers; and
depositing a conductive electrode within the trench.
2. A method according to claim 1 in which the thermally stable filler material is deposited in direct contact with the sidewalls.
3. A method according to claim 1, in which the step of annealing the filler material is performed at a temperature of less than 500 C; and the step of forming the spacers is performed by atomic layer deposition.
4. A method according to claim 3, in which the step of heating the filler material is performed in-situ on a spin-on track during the step of trench filling.
5. A method according to claim 1, in which the step of forming the spacers is performed by depositing high-k material.
6. A method according to claim 2, in which the step of forming the spacers is performed by depositing high-k material.
7. A method according to claim 3, in which the step of forming the spacers is performed by depositing high-k material.
8. A method according to claim 5, in which the step of forming the spacers is performed by depositing a material selected from the group comprising Al2O3, HfO2, ZrO2 and La2O3 and their silicates.
9. A method according to claim 6, in which the step of forming the spacers is performed by depositing a material selected from the group comprising Al2O3, HfO2, ZrO2 and La2O3 and their silicates.
10. A method according to claim 7, in which the step of forming the spacers is performed by depositing a material selected from the group comprising Al2O3, HfO2, ZrO2 and La2O3 and their silicates.
11. A method according to claim 1, in which a step of performing a bottle etch precedes the step of depositing a thermally stable filling material.
12. A method according to claim 1, in which the step of heating the filler material is performed at a temperature of less than 800 C and the step of forming the spacers is performed by low pressure deposition of nitride or oxide at a temperature of less than 800 C.
13. A method according to claim 12, in which a step of performing a bottle etch precedes the step of depositing a thermally stable filling material.
14. A method of forming an integrated circuit containing a DRAM array comprising the steps of:
a) forming a capacitor by:
etching a trench having substantially vertical sidewalls;
depositing a thermally stable filler material in the trenches;
heating the filler material in an oxidizing ambient;
recessing the filler material down to a capacitor top level;
forming spacers on the trench sidewalls;
stripping the filler material;
doping the trench sidewalls below the spacers; and
depositing a conductive electrode within the trench;
b) forming a transistor connecting a bitline to the conductive electrode; and
completing the integrated circuit.
15. A method according to claim 14, in which the thermally stable filler material is deposited in direct contact with the sidewalls.
16. A method according to claim 14, in which the step of annealing the filler material is performed at a temperature of less than 500 C; and the step of forming the spacers is performed by atomic layer deposition.
17. A method according to claim 16, in which the step of heating the filler material is performed in-situ on a spin-on track during the step of trench filling.
18. A method according to claim 16, in which the step of forming the spacers is performed by depositing high-k material.
19. A method according to claim 17, in which the step of forming the spacers is performed by depositing high-k material.
20. A method according to claim 19, in which the step of forming the spacers is performed by depositing a material selected from the group comprising Al2O3, HfO2, ZrO2 and La2O3 and their silicates.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A polymer comprising the monomer units
where n is an integer from 1 to 4, R is a branched or unbranched, saturated or unsaturated, optionally oxygen-interrupted hydrocarbyl radical having from 1 to 20 carbon atoms, and the dashed lines in monomer units A1, A2 and A3 indicate attachment points to other monomer units.
2. The polymer according to claim 1, which is based on polyalkyleneimine.
3. The polymer according to claim 1, which has an average molecular mass in a range from 500 gmol to 500 000 gmol.
4. The polymer according to claim 1, wherein n=1 andor R is C1-C20 alkyl.
5. The polymer according to claim 1, which has a log P value of from \u22123 to 6.5.
6. The polymer according to claim 1, wherein the polymer further comprises uncharged monomer units and wherein the ratio of positively charged monomer units to uncharged monomer units is at least 0.25.
7. The polymer according to claim 1, wherein the polymer further comprises monomer units other than A1, A2 and A3 and wherein R is present two or three times in at most 25% of such monomer units.
8. The polymer according to claim 1, wherein the proportion of each of the monomer units A1, A2, A3 in the polymer is in each case independently in the range from 0.01 to 0.5.
9. A process for preparing a polymer according to claim 1, comprising
a) reacting a polymer comprising the monomer units
where n is an integer from 1 to 4 with hydrogen cyanide and formaldehyde, and the dashed lines in monomer units A1, A2 and A3 indicate attachment points to other monomer units;
b) reacting the product from a) with a reagent for introducing the R group, R being a branched or unbranched, saturated or unsaturated, optionally oxygen-interrupted hydrocarbyl radical having from 1 to 20 carbon atoms.
10. A method of textile bleaching or paper bleaching, comprising contacting textile or paper with a bleaching composition comprising the polymer according to claim 1.
11. The polymer according to claim 1, which is based on polyethyleneimine.
12. The polymer according to claim 11, wherein R is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl and wherein n is 1 in all of A1, A2 and A3.
13. The polymer according to claim 1, wherein R is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl.
14. The polymer according to claim 1, wherein n is 1 in all of A1, A2 and A3.
15. A bleaching composition, comprising the polymer according to claim 1 as a bleach activator.
16. The bleaching composition as claimed in claim 15, further comprising a bleach.